Prima BioMed (IMMP)
(Delayed Data from NSDQ)
$1.89 USD
+0.02 (1.07%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $1.89 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Prima BioMed Ltd falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | |
---|---|---|---|---|---|
Sales | NA | 4 | 5 | 3 | 11 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 4 | 5 | 3 | 11 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 30 | 28 | 18 | 19 |
Income After Depreciation & Amortization | 0 | -27 | -23 | -15 | -8 |
Non-Operating Income | NA | 0 | 0 | -8 | -1 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -27 | -23 | -22 | -9 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -27 | -23 | -22 | -9 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -27 | -23 | -22 | -9 |
Depreciation Footnote | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -25 | -22 | -15 | -7 |
Depreciation & Amortization (Cash Flow) | NA | 1 | 2 | 0 | 1 |
Income After Depreciation & Amortization | 0 | -27 | -23 | -15 | -8 |
Earnings Per Share Data | 6/30/24 | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 |
---|---|---|---|---|---|
Average Shares | NA | NA | 84.99 | 59.45 | 40.10 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.27 | -0.38 | -0.22 |
Diluted Net EPS (GAAP) | NA | -0.30 | -0.28 | -0.38 | -0.23 |
Fiscal Year end for Prima BioMed Ltd falls in the month of June .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | NA | NA |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | NA | NA | NA | NA | NA |
Extras & Discontinued Operations | NA | NA | NA | NA | NA |
Net Income (GAAP) | NA | NA | NA | NA | NA |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | NA | NA | NA | NA | NA |